-
Mashup Score: 0
As lawmakers and industry groups seek to get a handle on U.S. | As lawmakers and industry groups seek to get a handle on U.S. drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
As lawmakers and industry groups seek to get a handle on U.S. | As lawmakers and industry groups seek to get a handle on U.S. drug shortages, a new white paper from German market analytics firm QYOBO supports the thesis that disproportionately low prices for generic medicines can make it difficult for drugmakers to keep supplies afloat.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
Sinking prices for generic meds a major factor in US shortage crisis: report https://t.co/xmAkMQtVSd
-
-
Mashup Score: 8Warren rebukes GSK for alleged 'money grab' after company pulled popular asthma med - 4 month(s) ago
In the aftermath of GSK’s decision to drop its brand-name asthma inhaler Flovent HFA in favor of an authorized generic, Sen. | After GSK’s decision to drop its brand-name asthma inhaler Flovent HFA in favor of an authorized generic, Sen. Elizabeth Warren (D-Mass.) has accused the British drugmaker of engaging in a “shameful money grab.” GSK, for its part, disagrees with the senator’s assessment.
Source: www.fiercepharma.comCategories: General Medicine News, NephrologyTweet-
RT @realdocspeaks: https://t.co/U4kHMfdzZO. The authorized generic of Fovent is $310 versus $340 for the brand. The brand was discontinued…
-
-
Mashup Score: 3FDA proposes cell and gene therapy site tours to help regulators learn from industry - 4 month(s) ago
It’s no secret that cell and gene therapies have faced manufacturing hurdles as the advanced medicines have become increasingly popular in recent years. | It’s no secret that cell and gene therapies have faced manufacturing hurdles as the advanced medicines have become increasingly popular in recent years. Now, the FDA is proposing to work directly with industry through a series of facility tours that could enable both sides to learn something from each other.
Source: www.fiercepharma.comCategories: General Medicine News, Oncologists1Tweet-
The Office of Therapeutic Products (OTP) of the FDA’s Center for Biologics Evaluation and Research (CBER) unveiled its Cellular and Gene Therapies Interactive Site Tours Program. Read more: https://t.co/THrifHf15J
-
-
Mashup Score: 1Umpteenth time’s a charm? Lawmakers try to block DTC drug ad tax deductions yet again - 4 month(s) ago
Lawmakers are mounting yet another attempt to change the rules on taxing drug ads. | Lawmakers are mounting yet another attempt to change the rules on taxing drug ads. Claiming that Big Pharma is exploiting a loophole, Democrats and independents in the Senate and House have introduced bills that would stop companies from deducting direct-to-consumer ad spending from their tax calculations.
Source: www.fiercepharma.comCategories: General Medicine News, Rare DiseaseTweet-
RT @FiercePharma: Umpteenth time’s a charm? Lawmakers try to block DTC drug ad tax deductions yet again https://t.co/09YTffdNCP
-
-
Mashup Score: 0Move over, oncology: Obesity, diabetes meds will take over 2030's top drug rankings, Evaluate forecasts - 4 month(s) ago
It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. | Novo Nordisk’s Ozempic is slated to take over No.1, while Merck’s Keytruda falls to No.9 on Evaluate’s predicted rankings of top drugs by 2030 sales.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
Move over, oncology: #Obesity, #diabetes meds will take over 2030's top drug rankings, Evaluate forecasts | #weightloss #pharma #GLP1s https://t.co/hwHgh3fe6v
-
-
Mashup Score: 1Move over, oncology: Obesity, diabetes meds will take over 2030's top drug rankings, Evaluate forecasts - 4 month(s) ago
It’s well known that obesity drugs from Novo Nordisk and Eli Lilly are on a high-flying growth trajectory that doesn’t look to be letting up anytime soon. | Novo Nordisk’s Ozempic is slated to take over No.1, while Merck’s Keytruda falls to No.9 on Evaluate’s predicted rankings of top drugs by 2030 sales.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
#Obesity, and #diabetes medications will take over 2030's top drug rankings, according to @FiercePharma https://t.co/sRBbCKdkXl
-
-
Mashup Score: 0Leveraging technology to make healthcare more accessible - 4 month(s) ago
Ron Gutman is a pioneer in the healthcare tech space. | Ron Gutman, Co-CEO and Co-Founder of Intrivo and mastermind of its hero product – the On/Go test-to-treat digital platform, outlines some of the key trends and developments that he believes will shape the world of healthcare delivery in 2024, AI being chief among them.
Source: www.fiercepharma.comCategories: General Medicine News, Cardiologists1Tweet-
Leveraging technology to make healthcare more accessible | Fierce Pharma https://t.co/rWeFu4sbFc
-
-
Mashup Score: 1Merck's Capvaxive gears up to challenge Pfizer's dominant Prevnar with CDC panel backing - 4 month(s) ago
After scoring approval as the world’s first pneumococcal disease vaccine made specifically for adults earlier this month, Merck’s Capvaxive passed the next test in its bid to take on Pfizer an | The recommendation sets up Merck’s new pneumococcal disease vaccine to potentially capture some of Pfizer’s market share.
Source: www.fiercepharma.comCategories: General Medicine News, Infectious DiseaseTweet-
“the vaccine experts recommended the shot for adults 65 and older who have not yet received a pneumococcal conjugate vaccine, plus for those 19 to 64 with certain underlying medical conditions or other risk factors.” https://t.co/KPIh7NRIFv
-
-
Mashup Score: 0
After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. | After losing round one of its respiratory syncytial virus (RSV) vaccine bout with GSK, Pfizer is rallying. And what better way to do it than to win a major contract in your rival’s home country? The U.K. government has selected Pfizer to supply 5 million doses of its RSV shot Abrysvo over the next two years.
Source: www.fiercepharma.comCategories: General Medicine News, Infectious DiseaseTweet-
“In the fourth quarter of last year, however, Pfizer showed its was making progress as its sales of Abrysvo increased sequentially from $375 million to $515 million. The boost was aided by an FDA approval of Abrysvo in August to vaccinate pregnant mothers” https://t.co/zqLu84B4xx
-
Sinking prices for #generics meds a major factor in #US #shortages crisis: report | #pharma https://t.co/PJ8bjG5uhU